ArticleCureus2025
Thrombotic Thrombocytopenic Purpura Without Neurological Involvement: A Case Report and Review of the Diagnostic and Treatment Strategies.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes the presentation of thrombotic thrombocytopenic purpura (TTP) without neurological involvement in a 48-year-old woman. TTP is a relatively rare, life-threatening condition that comprises thrombotic microangiopathy (TMA) and enzymatic dysfunction of ADAMTS13 (a disintegrin-like metalloproteinase with thrombospondin motif type 1, member 13, which regulates platelet aggregation). Another similar condition that presents with TMA in adults is atypical hemolytic uremic syndrome. It is challenging to differentiate between the two conditions clinically, especially in the absence of neurological symptoms. However, plasma exchange is the initial lifesaving treatment for both in acute situations. Our patient had a history of bruising, which was evident in clinical examination, without any other positive findings. However, ADAMTS13 activity was 0%, and the platelet count was 4 × 10⁹/L on arrival. Timely investigation and treatment not only saved her life but also reduced end-organ damage. This report provides an overview of the acute presentation of TTP, positive clinical findings, investigations, diagnosis, treatment, and post-treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.